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Extensive phenotypic 
characterisation of a human 
TDP‑43Q331K transgenic mouse 
model of amyotrophic lateral 
sclerosis (ALS)
Jodie A. Watkins, James J. P. Alix, Pamela J. Shaw & Richard J. Mead*
The majority of preclinical studies in ALS have relied on transgenic models with overexpression of 
mutant human superoxide dismutase 1 (SOD1), widely regarded to have failed in terms of translation 
of therapeutic effects. However, there are still no widely accepted models of other genetic subtypes of 
ALS. The majority of patients show ubiquitinated cytoplasmic inclusions of TAR DNA binding protein 
of 43 kilodaltons (TDP‑43) in spinal motor neurons at the end stage of disease and a small proportion 
have mutations in TARDBP, the gene encoding TDP‑43. TDP‑43 transgenic mouse models have been 
produced, but have not been widely adopted. Here, we characterised one of these models available 
from the Jackson Laboratory in detail. Compared to TDP‑43WT mice, TDP‑43Q331K mice had 43% less 
hindlimb muscle mass at 6 months and a 73% reduction in hindlimb compound muscle action potential 
at 8 months of age. Rotarod and gait analysis indicated motor system decline with elevated weight 
gain. At the molecular level, the lack of TDP‑43 cellular pathology was confirmed with a surprising 
increase in nuclear TDP‑43 in motor neurons. Power analysis indicated group sizes of 12–14 mice are 
needed to  detect 10–20% changes in measured parameters with a power of 80%, providing valid 
readouts for preclinical testing. Overall, this model may represent a useful component of multi‑model 
pre‑clinical therapeutic studies for ALS.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, causing progressive muscle weakness, spastic-
ity and eventual respiratory failure, usually resulting in death within 3–5 years of symptom  onset1.
Transactive response (TAR)-DNA-binding protein 43 (TDP-43) is a DNA/RNA binding protein, that is 
involved in mRNA processing, transcription and translational regulation. TDP-43 has been implicated in both 
ALS and frontotemporal lobar degeneration (FTLD). An overlap of the two diagnoses is increasingly recognised, 
with approximately 15% of patients with FTLD developing ALS and this extends to shared pathological, genetic 
and mechanistic  features2. The main pathological finding in ALS is the presence of ubiquitinated inclusions of 
TDP-43 in the cytoplasm of both neurons and glia of the brain and spinal cord. These inclusions are found in 
most sporadic cases, as well as non-SOD1 familial  ALS3, 4, regardless of whether the patient has a mutation in the 
TARDBP gene, which encodes the TDP-43 protein. However, several mutations in TARDBP have been identi-
fied as causal mutations associated with  ALS5–7. Thus, approximately 97% of ALS cases show TDP-43 pathology, 
the only exception being familial cases with SOD1  mutations3. This points to a possible mechanistic difference 
between SOD1-related ALS and all other subtypes of ALS. For this reason, the field urgently needs to identify 
a TDP-43 driven model for mechanism and therapeutic based studies. Such a model would complement the 
frequently used SOD1-related models.
Multiple TDP-43 mouse models have been generated to examine the role of TDP-43 in  ALS8 Several over-
expression models of wild-type or mutant TDP-43 have been investigated, resulting in a range of phenotypes 
including bodyweight changes, cytoplasmic TDP-43 inclusions, tremor, muscle atrophy, spasticity, impaired 
learning, impaired memory and premature  death9–14. TDP-43 loss-of-function has also been modelled by con-
ditional deletion of TDP-43 expression in adult mouse motor neurons, resulting in weight loss, muscle atrophy, 
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motor neuron loss, cytoplasmic ubiquitinated TDP-43 inclusions and premature  death15, 16. Thus, both increased 
and decreased expression of TDP-43 can lead to neuronal degeneration.
More recently a knock-in mouse model bearing a Q331K mutation in the endogenous mouse gene has been 
described, and is the most physiological model described to date, showing features of both ALS and FTD, with 
weight gain, lack of classical TDP-43 pathology and elevated nuclear TDP-4317.
Despite this extensive literature, no consensus has emerged as to which is the most suitable model, particu-
larly for use in testing potential new therapeutic agents. There appear to be several reasons for this: the first is 
that transgenic overexpression of either mutant or wild-type TDP-43 causes  neurodegeneration13, 14. Secondly, 
the most characterised  model18 has a significant non-motor phenotype related to degeneration of autonomic 
neurons of the myenteric plexus, which causes premature death due to inhibition of gut  transit19–21. Finally, the 
majority of models show considerable variability in the behavioural readouts, complicating their use in hypothesis 
driven or therapeutic research.
There is a need to characterise and validate TDP-43 driven models extensively, in order to determine their 
potential utility. Here, we investigate in detail the phenotypic characteristics of a mouse model transgenic for 
human TARDBP with a Q331K mutation (referred to as TDP-43Q331K), in comparison to wild-type TDP-43 
(TDP-43WT), expressed under the murine prion promoter. This mouse model was originally described on a 
C57BL/6 J  background22 but was deposited at the Jackson laboratories and subsequently backcrossed on to a 
different genetic background (C57BL/6 N).
In this study, we have undertaken a detailed assessment of this model. Our objectives were to confirm the 
previous findings on the new background, provide multiple quantitative readouts of disease progression, clearly 
define the motor phenotype and to outline the monitoring and assessment criteria for therapeutic trials and 
mechanistic assessments in this model.
Results
Abnormal gait evident at 27 weeks of age in TDP‑43Q331K mice. In both male and female mice, an 
intermittent resting tremor was evident by 10 weeks of age, which progressed to a pronounced continuous rest-
ing tremor by 14 weeks of age. Supplementary Movie 1 can be found online (supplementary data) and shows the 
resting tremor in a 6 month old TDP-43Q331K female mouse.
Male and female TDP-43Q331K mice developed an abnormal gait (neuroscore of 2) at around 27 weeks of age 
and progressed to develop an obvious waddling or “swimming” gait (Fig. 1A,B, Supplementary Movie 2, online) 
which can be quantified using gait analysis (see below). Conversely, TDP-43WT (Supplementary Movie 3, online) 
and non-transgenic mice showed no sign of tremor or gait abnormality (non-transgenic not shown).
TDP‑43Q331K show weight gain compared to TDP‑43WT mice. TDP-43Q331K mice were significantly 
heavier than non-transgenic and TDP-43WT from 10 weeks of age in males (TDP-43Q331K 29 ± 3.3 g vs TDP-43WT 
24.4 ± 0.7 g vs non-transgenic 24.7 ± 1.1 g, p < 0.05 overall, by two-way ANOVA, see figure for post-tests) and 
9 weeks of age in females (TDP-43Q331K 21 5 ± 2.0 g vs TDP-43WT 17.4 ± 1.3 g vs non-transgenic 17.8 ± 1.1 g, 
p < 0.05, overall, by two-way ANOVA, see figure for post-tests). This phenotype was not described originally in 
this model. The difference in weight continued to increase with age (Fig. 1C,D).
Rotarod performance decreases with age in the TDP‑43Q331K mice. TDP-43Q331K mice showed an 
age-dependent decrease in latency to fall on the accelerating rotarod compared to non-transgenic and TDP-
43WT mice by 7 weeks of age in males (TDP-43Q331K 147.8 ± 34.6 s vs TDP-43WT 261.0 ± 49.4 s vs non-transgenic 
244.3 ± 46.7, p < 0.01, two-way ANOVA) and 10 weeks of age in females (TDP-43Q331K 201.6 ± 36.9 s vs TDP-43WT 
264.8 ± 40.8 s vs non-transgenic 258.3 ± 29.2 s, p < 0.01, two-way ANOVA) (Fig. 1E,F).
It is possible that the rotarod findings were influenced by the weight of the mice, as a previous study reported 
a correlation between increased weight and decreased rotarod  performance23. Therefore, we corrected for weight 
by plotting the ratio of latency to fall (seconds)/weight (g) and the significant difference in rotarod performance 
found in the TDP-43Q331K mice was still evident (Fig. 1G,H).
Gait analysis. Using the CatWalk gait analysis system, it was possible to identify a number of gait abnor-
malities. Paw prints were wider, with an unsteady gait pattern in the TDP-43Q331K mice (Fig. 2C), compared to 
the gait of non-transgenic (Fig. 2A) and TDP-43WT transgenic mice (Fig. 2B). Walking duration (Fig. 2D,E) 
increased significantly in TDP-43Q331K mice by 6  months of age (p < 0.001) and this slowing of gait is more 
prominent by 10 months of age (p < 0.0001).
The hind-limb base of support is the distance between left and right hindlimbs perpendicular to the direc-
tion of travel and captures the severe waddling or swimming gait of the TDP-43Q331K mice. This measurement 
increases from ~ 21 mm to ~ 36 mm between 1 and 10 months of age in both male and female TDP-43Q331K mice 
and this increase is statistically greater than that seen in both sets of control mice at 6 and 10 months of age 
(Fig. 2F,G).
A useful indicator of unsteady gait is the percentage of time spent on diagonal paws, the predominant step-
ping pattern in healthy mice. The percentage of time spent on diagonal paws is decreased in male mice at 6 and 
10 months of age (p < 0.05) and at 10 months of age in female mice indicating an increasingly unsteady gait with 
age (p < 0.0001) (Fig. 2H,I).
Lumbar spinal motor neurons show increased levels of c‑myc‑tagged TDP‑43. Lumbar spinal 
cord sections from TDP-43WT and TDP-43Q331K mice showed clear nuclear staining (Fig. 3A) for c-myc-tagged 
human TDP-43 (green). C-myc-tagged TDP-43 was also seen in the cytoplasm of motor neurons, identified 
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by their size, morphology and location. Nuclear staining intensity of c-myc-tagged TDP-43 was significantly 
higher in TDP-43Q331K spinal cord motor neurons (p < 0.01) (Fig. 3B). However, there was no significant differ-
ence in cytoplasmic staining intensity of c-myc-tagged TDP-43 between groups (Fig. 3C). Surprisingly, the ratio 
Figure 1.  Body weight, CatWalk gait analysis and rotarod performance. (A) Male neuroscores. (B) Female 
neuroscores. (C) Male body weight. (D) Female body weight. (E) Male rotarod performance. (F) Female rotarod 
performance. (G) Male rotarod performance/weight. (H) Female rotarod performance/weight. Error bars 
represent mean ± SD. All graphs contain data for TDP-43Q331K (n = 6 per gender—depicted by the blue lines), 
TDP-43WT (n = 6 per gender—depicted by the green lines) and non-transgenic (n = 12 per gender—depicted by 
the red lines) mice compared using a two-way ANOVA with Tukey’s post-tests. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 TDP-43Q331K vs all other groups.
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Figure 2.  CatWalk gait analysis showing paw print patterns; walking duration, hindlimb base of support and diagonal 
pattern walking in TDP-43Q331K mice compared to TDP-43WT and non-transgenic mice. Footprint traces of non-transgenic 
(A), TDP-43WT (B) and TDP-43Q331K (C) mice at 10 months of age. Red prints = right limbs, green prints = left limbs, bright 
prints = forelimbs, darker prints = hindlimbs. In TDP-43Q331K n = 6 males, 6 females, NTg n = 12 males, 12 females, TDP-43WT 
n = 6 males, 6 females. Analysis of individual gait parameters over time in the TDP-43Q331K, TDP-43WT and non-transgenic 
mice. Mean (± SD) walking duration (time to walk a distance of 43.8 cm) in seconds was measured in males (D) and females 
(E). Mean (± SD) hindlimb base of support (distance between hind paws) was measured in males (F) and females (G). Mean 
(± SD) diagonal stepping pattern in males (H) and females (I). *p < 0.05 vs all other groups, **p < 0.01 vs all other groups, 
***p < 0.001 vs all other groups, ****p < 0.0001 vs all other groups, two way ANOVA with Tukey’s post-tests. 
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of nuclear/cytoplasmic staining intensity of c-myc-tagged TDP-43 was also significantly higher in TDP-43Q331K 
motor neurons (p < 0.01) (Fig. 3D).
Human TARDBP transgene and TDP‑43 protein expression. The original report describing this 
model indicated that the level of expression of the introduced transgene and protein were not significantly dif-
ferent between the TDP-43Q331K and TDP-43WT  lines22. In order to compare the level of transgene expression 
between lines, human TDP-43 (huTDP-43) transcript levels were measured by RT-qPCR in the cortex, spinal 
cord and hindlimb muscles of TDP-43Q331K and TDP-43WT mice at 10 months of age (Fig. 4A–C). Expression of 
huTDP-43 transcripts was over threefold higher in the TDP-43Q331K cortex compared to the TDP-43WT cortex 
(308.4 ± 36.4% vs 100 ± 17.3%, p < 0.0001), twofold higher in the TDP-43Q331K spinal cord compared to the TDP-
43WT spinal cord (213.3 ± 65.8% vs 100 ± 13.3%, p < 0.0001), and fourfold higher in the TDP-43Q331K hindlimb 
muscle compared to the TDP-43WT hindlimb muscle (407.6 ± 111.9% vs 100 ± 19.8%, p < 0.0001).
Western blotting with an anti-TDP-43 antibody allowed for quantification of both human and mouse TDP-43 
protein due to the c-myc tag on the human protein increasing its molecular weight (Fig. 4D–F). Moderate levels of 
human TDP-43 were measured in the TDP-43WT mice at 10 months of age (66.6 ± 21.0% in cortex, 126.1 ± 67.1% 
in spinal cord compared to endogenous mouse TDP-43), whilst levels in the TDP-43Q331K mice were significantly 
higher than endogenous mouse TDP-43 in cortex (151 ± 56.5%, p < 0.001) but not in spinal cord (213.9 ± 154.1%). 
Figure 3.  Immunohistochemical staining of lumbar spinal cord to detect human TDP-43. 
Immunohistochemical staining of DAPI, NeuN and c-myc in the lumbar ventral horns of 10 month old TDP-
43WT and TDP-43Q331K male and female mice (n = 5/group). Panels in (A) show example staining from one male 
TDP-43Q331K, one male TDP-43WT, one female TDP-43Q331K and one female TDP-43WT lumbar spinal cord. Scale 
bars are 100 µm (first column), and 20 µm (columns 2 and 3). Nuclear (B) and cytoplasmic (C) quantification 
using automated pixel intensity counting (± SD) of c-myc-tagged hTDP-43 in the lumbar cord. (D) Ratio of 
nuclear/cytoplasmic staining of c-myc-tagged hTDP-43. Error bars represent mean ± SD, one way ANOVA, 
** = p < 0.01.
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Transgenic expression of human TDP-43 resulted in a significant reduction in endogenous mouse TDP-43 in the 
TDP-43WT cortex (47.5 ± 39.6% in cortex, p < 0.05) but not significantly in the spinal cord (65.5 ± 16.3%) compared 
to non-transgenic. Expression of endogenous TDP-43 was significantly reduced in the cortex of TDP-43Q331K 
mice (13.6 ± 5.6%, p < 0.001) but not in spinal cord (70.7 ± 29.6%). Total TDP-43 levels (mouse plus human) were 
significantly higher in the TDP-43Q331K mice (164.6 ± 56.6% in cortex, p < 0.05, 284.5 ± 173.3% in spinal cord, 
p < 0.01, versus endogenous mouse), compared to non-transgenic mice but not significantly higher than in the 
TDP-43WT mice (114.1 ± 55.8% in cortex, 191.6 ± 78.5 in cord).
Figure 4.  hTDP-43 expression, hTDP-43 and mTDP-43 protein quantification, Tbc1d1 expression. (A–C) 
RT-qPCR for hTARDBP expression in TDP-43Q331K mice as a percentage of the mean TDP-43WT in cortex 
(A), spinal cord (B) and hindlimb muscles (C). ****p < 0.0001, Student’s t test. (D) Western blot showed two 
separate bands for human (44.2kD) and mouse TDP-43 (43kD). This example shows non-transgenic, TDP-43WT 
and TDP-43Q331K 10 month old cortex samples respectively (n = 3, 1 animal per lane). Note the same blot was 
processed and captured separately for TDP-43 and β-actin staining and these images are separated by white 
lines. Likewise the protein ladder lane was captured separately under normal illumination and aligned with the 
blot image. (E–F) Relative human, mouse and total TDP-43 protein levels in 10 m non-transgenic (n = 10 males, 
9 females), TDP-43WT (n = 5 males, 5 females) and TDP-43Q331K (n = 4 males, 5 females) mice in cortex (E), and 
spinal cord (F). All samples are normalised to the non-transgenic total TDP-43 value for each Western blot. 
(G–I) Tbc1d1 expression in TDP-43Q331K mice (n = 4 males, 5 females) as a percentage of the mean TDP-43WT 
levels (n = 5 males, 5 females) in cortex (G), spinal cord (H) and hindlimb muscle (I) showed no differences on a 
student’s t test. All data shown are mean ± SD.
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Tbc1d1 gene expression was equal in all tissues measured. In previous studies conditional knock-
out of tardbp caused leanness and lethality due to altered fat metabolism as a result of reduction in tbc1d1 levels, 
a known regulator of glucose 4 transporter (GLUT4) translocation in skeletal  muscle24. Transgenic overexpres-
sion of TDP-43 with an A315T mutation had the opposite effect with increased fat deposition, which correlated 
with elevated tbc1d1  expression25. In this study, tbc1d1 gene expression was not altered between mice expressing 
mutant or wild-type TDP-43 in cortex, spinal cord or muscle between groups (Fig. 4G–I).
TDP‑43Q331K mice lose over 40% of lower hind limb muscle mass. A significantly lower hindlimb 
muscle weight was evident in TDP-43Q331K mice compared to the TDP-43WT and non-transgenic mice at 
10 months of age (201.4 ± 17.2 mg TDP-43Q331K vs 339.7 ± 25.8 mg TDP-43WT vs 341.5 ± 38.3 mg, p < 0.0001, 
one-way ANOVA), (Fig. 5A).
TDP‑43Q331K mice have reduced compound muscle action potential (CMAP) amplitude and fas-
ciculations. In order to confirm that the loss of muscle mass correlated with reduced electrophysiological 
properties, CMAP amplitude was measured. A significant reduction in CMAP amplitude in the TDP-43Q331K 
mice compared to non-transgenic mice was evident in mice aged 9–11 months (7.9 ± 1.7 mV vs 29.8 ± 2.8 mV, 
p < 0.001, two-way ANOVA). This represents a 73% reduction in CMAP amplitude in the TDP-43Q331K mice 
(Fig.  5B). Loss of CMAP amplitude can be a non-specific observation relating, for example, to motor axon 
loss, or muscle dysfunction. To explore the aetiology of CMAP data we undertook hindlimb electromyography 
(EMG) in 8 mice. Clear fasciculation potentials were recorded in 2 of the eight mice (Fig. 5C,D).
Optimal study design based on statistical power analysis. One of the key determinants of model 
utility is the ability to detect therapeutic or other intervention effects with relatively high statistical confidence 
with reasonable group sizes. For the data generated here we undertook statistical power analysis to identify 
numbers of animals needed to detect a range of effect sizes (Table 1). We focussed on female mice overall as 
they showed less variability in the various readouts (e.g. see Fig. 1) meaning that smaller group sizes would be 
needed for a given effect size and statistical power. We calculated coefficients of variation (CV) for each readout 
and these are low overall with none above 16% and 6/8 below 11% (Table 1). Power analysis assuming a two-
tailed Student’s t test with α = 0.05 and β 0.8 was performed on 6 and 10 month data with effect sizes between 
Figure 5.  Muscle weights and electrophysiology. (A) Mean (± SD) gastrocnemius/soleus muscle weights of 
female mice at 10 months of age TDP-43Q331K n = 10, NTg n = 12, TDP-43WT n = 6. (B) Compound muscle 
action potential (CMAP) of the lower hindlimb of TDP-43Q331K mice and non-transgenic mice (± SD) at 
9–11 months of age (n = 3). ***p < 0.001 vs all other groups, ****p < 0.0001 vs other groups, one way ANOVA 
with Tukey’s post-tests. (C, D) Fasciculation potentials recorded in two out of eight TDP-43Q331K mice tested. 
Such electrophysiological activity was not seen in TDP-43WT mice. Mice were tested for CMAP and fasciculation 
at the same time point.
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10 and 20%. We have previously used time taken to reach a 20% decline in performance for rotarod data,26 and 
so we used this parameter in the present study as it mitigates the relatively high variability seen on individual 
timepoints. We noted that a 10 month study does not provide significant additional information over a study 
length of 6 months, with the exception that time to reach a neuroscore of 2 would be missed. A group size of 
14 per group is sufficient to capture the lowest effect size (10%) for all measured parameters. Thus, overall we 
would recommend group sizes of 14 with a 6 month study duration as being able to capture low effect sizes with 
reasonable confidence in as short a study as possible.
Discussion
For many years, models based on overexpression of mutant  SOD127 have been the major workhorse for preclini-
cal testing in ALS. This model has provided useful insights, however, the lack of translation of therapeutic effects 
from this model to clinical ALS indicates a need for new therapeutic testing  paradigms28. This may be particularly 
true given that SOD1-related ALS is not a TDP-43  proteinopathy3. Previously, serious flaws in experimental 
design were identified with the majority of studies in SOD1 related  models29, mandating that new models must 
be carefully characterised and serious attention paid to study design. There are currently nine TDP-43 mouse 
models readily available at The Jackson Laboratory (USA) for which the original papers are available, including 
the model described here.
Two models overexpressing wild type TDP-4312, 13 showed a dose-dependent phenotype with some evidence 
of TDP-43 pathology, indicating that overexpression of TDP-43 alone can cause an ALS-like disease. Mutant 
TDP-43 models which highly overexpress the TARDBP gene show severe  phenotypes9, 30. It has been reported 
that a truncated TDP-43 model has a mild motor phenotype, but the TDP-43 protein was unaffected and the 
truncation is not one found in ALS  patients31. Aggressive disease progression and early death has been an issue 
for several models including two with an M337V mutation under the murine prion  promoter14, 30 and a postnatal 
deletion of TDP-43 which caused a fatal increase in fat  metabolism24. A mouse model with an A315T mutation 
expressed using the murine prion  promoter18 was the first published and has been studied by multiple groups. 
However this mouse suffers from gut immotility, due to increased huTDP-43 expression in the myenteric plexus 
and degeneration of neurons therein, complicating the  phenotype19–21, 32.
The TDP-43 mouse model described in this paper has a minimal overexpression of the human TARDBP 
gene for both the mutant and wild-type transgenics, where the authors targeted a level of expression similar to 
endogenous mouse TDP-4322. Furthermore, the Q331K mutation has been found in  patients7, and these mice 
showed no signs of gastrointestinal problems.
In contrast to the original study describing these mice we found that the level of expression of transcripts 
encoding human TDP-43 were higher in TDP-43Q331K transgenic mice compared to TDP-43WT mice in both 
Table 1.  Numbers of mice/group required for investigation of each parameter. All power analyses are based on 
detecting a power of 80% in females, using the highest standard deviation (SD) from the relevant time-point.
Parameter Age (months)
Mean values in TDP-43Q331K 
mice (± SD) Coefficient of variation (%)
Mean difference TDP-43WT vs 
TDDP-43Q331K (%)
N required to detect an x% 
improvement
Time to reach a neuroscore of 2 
(severe waddle)













Increase by 2 weeks in time to 
reach a 20% decline in rotarod 
performance from maximum
N/A 11.4 weeks ± 1.8 15.9 N/A 11
CatWalk hindlimb base of 
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Gastrocnemius/ soleus muscle 
weight
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cortex and spinal cord and higher at the protein level in cortex. This calls into question whether this is a mutant 
specific phenotype, one of the initial attractions in characterising this model and should be considered when 
selecting controls.
Despite this, the TDP-43Q331K mouse on the C57BL/6 N background shows promise as a model of ALS as it 
demonstrates signs of reduced muscle mass, muscle weakness and motor dysfunction. The most interesting aspect 
of these findings is that they occur without the presence of canonical TDP-43 proteinopathy. It is conceivable that 
the model will develop TDP-43 pathology at a later time-point, as shown in a similar strain of TDP-43Q331K on 
a C57BL/6 J background at 24 months of  age33. These mice (line 31) were generated at the same time as the line 
tested here (line 103) and are described briefly in the Arnold et al.  paper22 although not characterised. Therefore, 
it is possible that the findings we present here are representative of an early stage of disease, in which a motor 
phenotype is evident prior to mislocalisation and aggregation of TDP-43. The development of an early phenotype 
is advantageous as it will allow us to investigate the onset and early stages of disease, as well as providing the 
potential to investigate disease modifiers such as gene-environment and gene–gene interactions.
Previous investigations of TDP-43Q331K mice on a C57BL/6 J background found no evidence of nuclear deple-
tion of TDP-4322. We found increased cytoplasmic TDP-43 in the TDP-43Q331K mice compared to the TDP-43WT 
mice, at 10 months of age, as described previously in a similar model at 24 months of  age33. However, we also 
report increased nuclear TDP-43 in the TDP-43Q331K mice compared to the TDP-43WT mice. Overall this may 
suggest that mislocalisation per se is not required for the onset of motor system degeneration, but the absolute 
level of TDP-43 in any one compartment (cytoplasmic or nuclear) may be the driving factor. This would fit in 
with a dominant negative model of TDP-43  dysfunction34. This finding has been highlighted also in a knock-
in mouse model where the Q331K mutation has been introduced into the endogenous mouse tardbp  gene17. 
Interestingly these mice also demonstrate increased weight gain and a lack of TDP-43 mislocalisation. This may 
suggest that mild overexpression of TDP-43 via a transgenic approach is physiologically relevant and we believe 
these findings have wider implications for TDP-43 biology.
The results we present here consistently demonstrate a detectable decline in motor performance by 6 months 
of age in the TDP-43Q331K mice. Progressive gait abnormalities become identifiable on neuroscoring at around 
6 months of age, consistent with the significant changes seen in hindlimb base of support and walking duration 
on quantitative gait analysis, and a 40% loss of gastrocnemius muscle mass.
Rotarod performance is significantly reduced in the TDP-43Q331K mice by 10 weeks of age, consistent with 
findings in a previous study of TDP-43Q331K mice on a C57BL/6 J background, in which the mice were found to 
have a significantly reduced rotarod performance at 3 months of  age22.
We observed that ‘walking duration’, increases as TDP-43Q331K mice age when compared to both TDP-43WT 
and non-transgenic mice. This suggests a reduction in speed which may be related to motor dysfunction and/or 
a reduced motivation. In addition, during normal gait, mice predominantly walk with diagonally opposite paws 
in contact with the ground at any one time in a diagonal stepping pattern. Both male and female TDP-43Q331K 
mice showed a reduction in this gait type with aging suggesting increasingly unsteady gait with age.
A link between manipulation of TDP-43 and tbc1d1 expression has previously been described in mouse 
models where deletion of tardbp decreased tbc1d1 expression and transgene mediated overexpression of tardbp 
lead to increased tbc1d1  levels24, 25. The tbc1d1 gene encodes a regulator of the translocation of Glut4, a glucose 
transporter and so this has been proposed as the mechanism by which TDP-43 regulates fat  deposition24, 25.
We observed increased weight gain in the TDP-43Q331K model described here with mild overexpression of 
mutant TDP-43 and investigated whether tbc1d1 gene expression was also elevated as a potential mechanism 
causing weight gain. Levels of tbc1d1 expression were similar between TDP-43Q331K mice when compared to 
TDP-43WT mice in cortex, spinal cord and hindlimb muscles. In this model at least there is no correlation between 
levels of huTDP-43, tbc1d1, and the observed weight gain. Further work is needed to identify the mechanism 
of weight gain. However, we know that TDP-43 pathology defines subtypes of FTD and ALS-FTD patients, in 
contrast to ALS patients, show significantly elevated  BMI35, 36 and a recent TDP-43Q331K non-overexpressing 
model also showed weight gain, which was hypothesised as an FTD-related feature as suggested by other FTD-
like phenotypes in this  model17.
CMAP amplitude quantifies the depolarisation of muscle fibres and a reduction in CMAP amplitude may 
correlate with loss of functional motor axons, as is often seen in ALS  patients37. CMAP amplitude was signifi-
cantly lower in TDP-43Q331K mice compared to non-transgenic mice at 9–11 months of age. This may indicate 
either fewer functional motor axons, as has been demonstrated previously in the  SOD1G93A mouse  model38, 39, or 
functional deficits at the level of the neuromuscular junction or muscle. EMG recordings at 6 months revealed 
fasciculation potentials, evidence of neurogenic (as opposed to myopathic) dysfunction.
A recent study used the same TDP-43Q331K mice described here to investigate the effect of heterozygous dele-
tion of Sarm 1 on axonal degeneration. Sarm1 is activated during Wallerian degeneration and its deletion was 
shown to protect motor axons and neuromuscular junctions from degeneration. The mice were also shown to 
display FTD-like phenotype with enhanced weight gain, brain atrophy and cognitive  impairments40.
Our findings show consistent disease progression in both male and female TDP-43Q331K mice. The data from 
the female mice are less variable, particularly for weight and rotarod performance. This indicates that, in some 
studies, it may be more efficient to use females alone.
Statistical power analysis for estimation of group sizes needed to detect different effect sizes indicated that 
differences of 10% can be detected at 6 months of age in neuroscoring, body weight, CatWalk hindlimb base of 
support and gastrocnemius/soleus muscle weights with group sizes of 14 for a pair-wise analysis (Student’s T 
Test). An extension of 2 weeks in time to reach a 20% decline in rotarod performance would require 11 mice per 
group. Therefore, we recommend group sizes of 14 females to detect any potential disease-modifying effect in 
a 6 month therapeutic study with reasonable power (80%). The reliability of multiple readouts of motor system 
function makes the model attractive for researchers interested in pursuing therapeutic or mechanistic studies. 
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The ‘3Rs’ of reduction, replacement and refinement are critical in preclinical research, and we demonstrate that 
a large body of data can be obtained with 14 animals per group, which compares favourably with the group sizes 
recommended in the SJLBL6  SOD1G93A mice of 24 per  group29. Furthermore, refinement is applied by using a 
mild disease model in which mice do not reach a distressing ‘end-stage’ and we suggest that therapeutic studies 
do not need to continue beyond 6 months.
In summary, this study provides a comprehensive analysis of this TDP-43Q331K transgenic model which should 
enable other laboratories to include it as a valid system for preclinical screening cascades with a view to clinical 
translation. The model has a number of advantages over other TDP-43 based systems. Firstly, it is a robust and 
reproducible model without confounding effects on gut motility. A range of quantitative readouts show low vari-
ability enabling well powered studies with reasonable group sizes for statistical analysis. It recapitulates features 
(increased nuclear TDP-43, weight gain) described in a model with an endogenous TDP-43Q331K  mutation17, 
confirming that it is physiologically relevant. Overall the wider adoption of this model should improve assess-
ment of novel therapeutic strategies for ALS, a key goal of translational ALS research.
Materials and methods
Please note that the material and methods section was adapted from the PhD Thesis of the first  author41 which 
can be found at http:// ethes es. white rose. ac. uk/ id/ eprint/ 16694 re-used here under a creative commons CC BY-
NC-ND 2.0 UK license (https:// creat iveco mmons. org/ licen ses/ by- nc- nd/2. 0/ uk/).
Ethics statement. All mouse experiments were carried out under the terms of the UK Animals (Scientific 
Procedures) Act 1986 and under a UK Home Office project license and ethically reviewed and approved by the 
University of Sheffield Animal Welfare and Ethical Review Body (AWERB). Mice were housed and cared for in 
accordance with the Home Office Code of Practice for Housing and Care of Animals Used in Scientific Proce-
dures. ARRIVE  guidelines42 were adhered to in the preparation of this  report41.
Transgenic C57BL/6 N mice. TDP-43WT (line 96) and TDP-43Q331K mice (line 103) (Mus musculus) were 
originally generated on a C57BL/6 J background by insertion of c-myc-tagged human TARDBP22 and were sub-
sequently backcrossed on to a C57BL/6 N background before being deposited at the Jackson Laboratory (stock 
numbers 017907 and 017933, respectively).
The basic characterisation tests were carried out with 5–7 males and 5–7 females per group (TDP-43WT and 
TDP-43Q331K), non-transgenic littermates of each mouse were also tested, the data for which were pooled to create 
the non-transgenic (NTg) group. Mice were recruited at 25 days of age.
The electrophysiology pilot study consisted of 3 female TDP-43Q331K mice and 3 female NTg mice at ages 
ranging from 9 to 11 months.
Tissue was collected for histological investigations at 1, 3, 6 and 10 months of age, collecting from 6 mice (3 
male, 3 female) from each group (non-transgenic, TDP-43WT, TDP-43Q331K) for each time  point41.
Housing. Mice were bred in a specified pathogen free environment, and transferred to a conventional facil-
ity for the studies described here. The facility uses a 12 h light/dark cycle, and room temperature is set to 21 °C. 
Cages were lined with fine sawdust (Eco-Pure Flakes 6, Datesand, Manchester, UK), which was changed weekly, 
a plastic house was placed in each cage and paper wool (Datesand, Manchester, UK) was used as bedding mate-
rial. Mice were fed 2018 rodent diet (Harlan, Bicester, UK) ad  libitum. Water was provided ad  libitum and 
changed weekly. Fresh bottles were provided every 2 weeks.
All mice were housed in same-sex littermate pairs or quadruplets. However, some male pairs were separated 
at around 6 months of age due to fighting, and were subsequently housed  singly41.
Genotyping. Mice were identified by ear clipping and the ear clip was then used for genotyping. DNA was 
extracted by incubating ear clips at 65 °C for 15 min in a 20 µl volume of QuickExtract DNA Extraction Solution 
(Epicentre, Cambridge, UK), followed by a 2 min incubation at 98 °C. 1 µl of DNA was then placed in solution 
with 4 µl of Firepol (Solis Biodyne, Tartu, Estonia), 11 µl of water, 0.5 µm of each huTDP-43 primer (forward 
5′-AGA GGT GTC CGG CTG GTA G-3′, reverse 5′-CCT GCA CCA TAA GAA CTT CTCC-3′) and 0.5  µm of each 
interleukin-4 receptor control primer (forward 5′-CTA GGC CAC AGA ATT GAA AGA TCT -3′, reverse 5′-GTA 
GGT GGA AAT TCT AGC ATC ATC C-3′).41. Transgene copy number was not assessed in the mice on this study.
Neuroscoring and weighing. Neuroscores and weight were monitored weekly in the morning, measur-
ing forelimb and hindlimb tremor on a scale of 0–3 (normal-strong). A ‘neuroscore’ scale was used to delineate 
motor dysfunction (0-normal, 1-significant hindlimb tremor, 2-abnormal gait, 3-severe waddle, 4-dragging of 
one hindlimb). These measurements were taken immediately prior to rotarod testing and in the same procedure 
room as the  rotarod41.
Accelerating Rotarod test. Mice were place on the accelerating rotarod (Jones & Roberts for mice 7650) 
for a period of up to 300 s. In this time the rotarod accelerates from 4 to 40 rpm and latency to fall was recorded 
for each mouse. All rotarod testing was carried out at a similar time of day (am) and all testing consisted of two 
trials, with the highest score being recorded for analysis.
Mice were initially trained on the rotarod over 3 days (27–29 days of age) and underwent the first testing day 
at 30 days of age, being tested each week  thereafter41.
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Gait analysis. The CatWalk gait analysis system 7.1 (Noldus Information Technology B.V., Wageningen, 
Netherlands) was used to capture gait parameters at 1, 3, 6 and 10 months of age. Mice were placed on the glass 
floor of the CatWalk system in complete darkness and left to walk/run freely. Whenever possible, 6 runs were 
recorded and 3 runs were selected for analysis. CatWalk software 7.1 was used to analyse the gait parameters of 
the mice. Walking duration is the time taken to cross the length of the recording window (43.8 cm)41.
Tissue collection for immunohistochemical staining. Mice were sacrificed by trans-cardiac perfu-
sion following anaesthetic overdose using an intraperitoneal injection of pentobarbitone (2.5  ml/kg). Under 
deep anaesthesia (checked by absence of pedal reflex) and prior to cessation of cardiac function, a thoracotomy 
was performed, in which the left ventricle was cannulated with a syringe containing PBS and mild pressure 
applied to distend the right auricle, which was then cut and the mouse was perfused with phosphate buffered 
saline (PBS) via the left ventricle of the heart, followed by perfusion with 4% PFA/PBS.
Spinal columns were then extracted and placed in 4% PFA/PBS overnight. Next the spinal cord was extracted 
from the spinal column and cryoprotected by immersion through a gradient of 5, 10, 15 and 20% sucrose/PBS for 
5 min in each concentration before overnight incubation in 20% sucrose overnight. The spinal cords were then 
dissected into cervical, thoracic, lumbar and sacral segments, and frozen in OCT embedding matrix (CellPath, 
UK) over dry ice, then stored at − 80 °C .
14 μm lumbar sections were sliced using a cryostat and mounted on to uncoated, charged slides (CellPath, 
Newtown, UK). Sections were mounted serially over a series of 5 slides, with 5 sections per slide, then stored 
at − 20 °C41.
Immunohistochemical staining for c‑myc and NeuN. Slides were placed at 37 °C for 30 min and then 
washed three times in PBS at room temperature with shaking. Sections were then permeabilised in 5% BSA, 
0.5% triton X-100/PBS for 90 min at 37 °C and subsequently placed in an antigen access unit (A. Menarini Diag-
nostics, Winnersh, UK) submerged in Access Revelation (MP-607- × 500, A. Menarini Diagnostics, Winnersh, 
UK) for a 30 min cycle at 125 °C, with a pressure of 20 psi.
After washes in PBS, slides were blocked with 5% BSA, 0.25% Triton X-100/PBS for 10 min and then incu-
bated with the primary antibodies diluted in 0.25% Triton X-100/PBS overnight at 4 °C (polyclonal rabbit 
anti-c-myc [Sigma catalogue #C3956, batch #093M4774V], monoclonal mouse anti-NeuN [Millipore catalogue 
#MAB377, batch #2592741] at 1:1000).
Following washes in PBS, slides were blocked in 5% BSA/PBS for 10 min and then incubated with secondary 
antibodies at room temperature for 90 min (Alexa Fluor donkey anti-rabbit 488 [Life Technologies A21206], 
Alexa Fluor donkey anti-mouse 555 [Life Technologies A31570], both at 1:1000 in 1% BSA).
Slides were then washed in PBS and filtered water. Sections were mounted in Vectashield hard set aqueous 
mountant with 4’,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Peterborough, UK) and left to dry 
at 4 °C overnight.
Images were captured using the INCell Analyzer 2000 (GE Healthcare, Hatfield, UK) and analysed using 
INCell analysis software. Image collection and analysis was carried out blinded. Images were produced using 
 ImageJ41.
Tissue collection. Mice were sacrificed at 10 months of age by overdose using an intraperitoneal injection 
of pentobarbitone (2.5 ml/kg) and exsanguination via cardiac puncture using a 25 gauge 0.5 × 16 mm needle (BD 
microlance, Ireland) and a 1 ml syringe (Terumo Europe, Belgium), after cessation of the pedal reflex. The brain 
was removed and the blunt edge of a steel back industrial single edge blade (Fisher Scientific, UK) was used to 
peel off the cortex from the remaining brain. An incision was made into the spine at the level of the hips and PBS 
was pushed into the spinal cavity using a 20 ml syringe (BD Plastipak, UK) fixed with a pipette tip (Fisherbrand, 
UK), ejecting the spinal cord from the rostral end of the spinal column.
Soleus/gastrocnemius muscles were removed together by dissection. Cortex, spinal cord and muscles were 
immediately snap frozen in liquid nitrogen and then stored at − 80 °C. Cortex and spinal cord from non-trans-
genic mice had been prepared using these methods from a previous cohort. Unfortunately non-transgenic snap 
frozen muscle tissue was  unavailable41.
RT‑qPCR. RNA was extracted using an RNeasy® lipid tissue mini kit (74804, Qiagen, UK) as per the man-
ufacturer’s instructions. Sample RNA concentrations were estimated using the Nanodrop spectrophotometer 
ND-1000 (Labtech International, UK). cDNA was extracted using a high capacity RNA-to-cDNA kit (4387406, 
Applied Biosystems, USA). Samples were placed in the PCR machine (G-storm, UK) for 1 h at 37 °C, followed 
by 5 min at 95 °C.
Primer pairs were mixed and diluted to 5 µM. Primers used were as follows: hTDP-43 (3′–5’ TGG GAT GAA 
CTT TGG TGC GT; 5′–3′ TTT GGC TCC CTC TGC ATG TT), mouse (total) TDP-43 (3′-5’ TAC CGG AAT CCC 
GTG TCT CA; 5′–3′ GAG GAA GCA TCT GTC TCA TCCA), TBC1D1 (3′-5’ GTG AGG AAG AGG CGT TCA AG; 
5′–3′ AGG TCT CGG TGG TAA TCG TG), GAPDH (3′-5’ ATG GTG AAG GTC GGT GTG AA; 5′–3′ TGG CAA CAA 
TCT CCA CTT TGC).
Samples were plated in duplicate in non-skirted, frosted, thin-wall 0.2 ml low profile 96 well plates (P3-0402, 
Geneflow, UK) and covered with optical wide area 8-cap strips (P3-0051, Geneflow, UK). Each well contained 
1 µl cDNA, 1 µl primer mix, 3 µl water and 5 µl brilliant III Ultra-Fast SYBR® Green QPCR Master Mix (600882, 
Agilent Technologies, USA). GAPDH was used as the house-keeping gene. A non-template control was plated 
for each primer pair.
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Samples were placed in the qPCR machine (Mx 3000P, Stratagene, USA) and run on the following protocol: 
95 °C for 10 min, 45 cycles (95 °C for 30 s, 58 °C for 1 min, 72 °C for 1 min), 95 °C for 1 min, 55 °C for 30 s, 
95 °C for 30 s.
Cycle threshold (Ct) values were extracted using MxPro Mx3000P software version 4.10 (Stratagene, USA). 
Further analysis was carried out using Microsoft Excel 2013 (Microsoft, USA) and GraphPad Prism 6 (Graph-
Pad, USA).
Mean Ct values were calculated for each sample from the duplicates. Data were not used if duplicate Ct values 
differed by ≥ 1. The relative concentration was calculated using the equation: 1/2(gene of interest Ct − GAPDH Ct). Values 
were presented as a percentage of the mean TDP-43WT value for each sample, or as a percentage of the mean 
non-transgenic value wherever  possible41.
Western blotting. Samples (n = 3 male, 3 female/group, 10  months of age) were homogenised in RIPA 
buffer (150 mM sodium chloride, 50 mM Tris, 1% triton x-100, 0.5% SDS, 0.5% sodium deoxycholate, pH 8.0) 
and homogenised, followed by passage through a syringe and needle at least 3 times. Samples were then rolled at 
4 °C for 30 min and left on ice for a further hour.
Samples were subjected to standard western blotting in 12% running gels and transferred to PVBDF mem-
branes and probed with rabbit anti-TDP-43 primary antibody (10782-2-AP, Proteintech, UK, 1/1000) in 5% (w/v) 
milk/TBST. Mouse anti-β-actin primary antibody (ab6276, Abcam, UK, 1/1000) and anti-mouse HRP conjugate 
secondary antibody (W402B, Promega, UK, 1/5000) was used as a loading control and signal quantified using 
GeneTools software (Syngene, UK)41.
Electrophysiology. Mice were placed under gaseous anaesthesia (1–2%, flow rate 1.0 L/min oxygen and 
nitrous oxide continuous inhalation through a nose cone). Body temperature was maintained using an electric 
heat pad (CWE, Ardmore, PA, USA) and a rectal temperature probe (Harvard Apparatus, Cambridge, UK) was 
used to supply feedback to the monitoring system (CWE, Ardmore, PA, USA). Compound muscle action poten-
tials (CMAPs) were recorded using a Dantec Keypoint Focus EMG System. Supramaximal stimuli were applied 
subcutaneously at the sciatic notch, ring recording electrodes were placed circumferentially around the distal 
hindlimb muscles, as described by Arnold et al.22. EMG recordings were performed in gastrocnemius muscles 
using a concentric needle electrode (Ambu Neuroline, UK)41.
Statistics. GraphPad Prism 6 was used for all statistical analyses (GraphPad, San Diego, CA, USA). Two-way 
ANOVA with Tukey’s post-test was used unless otherwise stated. All data are represented as a mean and stand-
ard deviation. Significance levels were set at 0.05, with two-tailed tests.
Power analysis was carried out using G*Power Version 3.1.9.2.43 using a Student’s t test, two-tailed, α = 0.05, 
β = 0.8 with equal N per group calculated for a range of putative effect sizes (10%, 15%, 20% difference from 
mean of the TDP-43Q331K mice)41.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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